Valeant Pharmaceuticals International, Inc. (NYSE:VRX) reported $1.76 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.72 by $0.04. The company had revenue of $1.85 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the prior year, the company posted $1.30 earnings per share. The company’s quarterly revenue was up 76.6% on a year-over-year basis. On average, analysts predict that Valeant Pharmaceuticals Intl will post $8.73 earnings per share for the current fiscal year. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) net profit margin is -13.10% and weekly performance is -4.32%. On last trading day company shares ended up $123.29. Analysts mean target price for the company is $52.38. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) distance from 50-day simple moving average (SMA50) is -3.77%.
On 2 JULY Alkermes plc (NASDAQ:ALKS) reported $0.11 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.10 by $0.01. The company had revenue of $130.21 million for the quarter, compared to the consensus estimate of $135.79 million. During the same quarter in the prior year, the company posted $0.40 earnings per share. The company’s quarterly revenue was down 20.3% on a year-over-year basis. On average, analysts predict that Alkermes Plc will post $0.49 earnings per share for the current fiscal year. Alkermes plc (NASDAQ:ALKS) shares fell 3.57% in last trading session and ended the day on $49.15. ALKS Gross Margin is 69.30% and its return on assets is -0.40%. Alkermes plc (NASDAQ:ALKS) quarterly performance is 18.35%.
On 25 JUNE Flamel Technologies SA (NASDAQ:FLML) announced that its once weekly formulation of exenatide, based on its Medusa drug delivery platform, has been successfully tested in minipigs. Exenatide is a glucagon-like peptide-1 agonist (GLP-1 agonist) used to treat type 2 diabetes. Flamel Technologies SA (NASDAQ:FLML) shares moved down 4.82% in last trading session and was closed at $14.21, while trading in range of $13.99 – $14.99. Flamel Technologies SA (NASDAQ:FLML) year to date (YTD) performance is 76.52%.
On 1 JULY PetMed Express, Inc. (NASDAQ:PETS) said it is working on improving the effectiveness of its campaigns. It has been quite successful in pushing its sales via the Internet. Approximately 80% of PetMed’s orders were generated on the website compared with 79% in the corresponding year-ago quarter. PetMed Express, Inc. (NASDAQ:PETS) ended the last trading day at $13.62. Company weekly volatility is calculated as 2.03% and price to cash ratio as 8.14. PetMed Express, Inc. (NASDAQ:PETS) showed a positive weekly performance of 2.64%.